CD8A and neoplasm: Given the capacity of tumor cells to create an immunosuppressive milieu in which immature myeloid cell accumulation provides inadequate activation of CD8+ T cells that leads to tumor-specific T cell dysfunction, we evaluated the therapeutic potential of direct intratumoral (i.t.)administration of rlipoE7m-MoGM to late-stage tumors.